FDA has agreed to let Australian biopharma ChemGenex seek approval for its oncology drug Omapro (omacetaxine) as a third-line therapy in chronic myeloid leukemia without a requirement for genetic testing. The agency issued a "complete response" in April on a second-line application, asking for a companion diagnostic test to select for patients with the Bcr-Abl T3151 mutation (1"The Pink Sheet" DAILY, April 12, 2010). Patients in the third-line setting are identified by their resistance to therapies rather than individual mutation status, CEO Greg Collier told analysts during a July 14 call. Based on discussions with the agency, the company will submit pooled data from two pivotal studies showing efficacy in patients who have failed prior treatment with two or more currently approved tyrosine kinase inhibitors. ChemGenex expects to file the NDA by the end of the year, while it continues to work with the agency to gain approval of the test that can move the second-line application forward. The third-line indication means a much larger patient population and commercial opportunity in the U.S., where there are no approved therapies in that setting, Collier said (2PharmAsia News, July 14, 2010). A European marketing application in the second-line setting is on track, with a potential approval in the first quarter of 2011
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Upcoming FDA user fee goal dates include novel products from a busy lung cancer pipeline, a single-dose passive immunization against RSV for infants, what could be the first oral HAE acute treatment, and a first-in-class HAE preventive antibody.
For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices.
Pink Sheet reporter and editors consider the issues that could emerge during upcoming private FDA forums with pharma CEOs, as well as the impact of the surprising move by HHS Secretary Robert F. Kennedy Jr. to limit the CDC recommendation for annual COVID-19 vaccine boosters.
